Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 178 participants.

Also called NCT01559298

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 178 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01559298
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01559298. Randomized; no masking; primary purpose prevention. Start 2012-03 (actual); primary completion 2015-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial
Acronym
ARTE
Condition
Aortic Valve Disease
Condition
Stroke
Intervention (Drug)
Aspirin (80 mg/d) + clopidogrel (75 mg/d)
Intervention (Drug)
Aspirin
Lead sponsor
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (class: other)
Collaborator
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct01559298
Content hash
f8e0a433c5fb1b21c233712c0a81ae7668d6207aff1f26d721c1f64336450805